Adolor kept at neutral by Merrill

Adolor Corp. was maintained at neutral by Merrill Lynch analyst Eric Ende. The company reported that Entereg demonstrated a statistically significant improvement (20 hours) in the acceleration of time to recovery of gastrointestinal function following bowel resection surgery, the primary endpoint. Merrill believes the market opportunity in post operative ileus is small and there will be competition. The key driver for Adolor should be data in opioid-induced bowel dysfunction, currently in phase 3. Shares of the Exton, Pa., biopharmaceutical company were up $6.53, or 41.43%, at $22.29 on volume of 7,002,787 shares versus the three-month running average of 366,177 shares. (Nasdaq: ADLR)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.